OncoPharm Capmatinib & SC Daratumumab
10 snips
May 8, 2020 The podcast dives into the groundbreaking FDA approval of daratumumab for subcutaneous use, showcasing its advantages over traditional IV administration. It also explores capmatinib, the first drug approved for MET exon 14 skipping mutations, and its role in treating targeted lung cancers. The discussion highlights the safety and efficacy of these innovative treatments, alongside essential patient monitoring and their potential integration into cancer care regimens.
AI Snips
Chapters
Transcript
Episode notes
Daratumumab SC Offers Advantages
- Daratumumab hyaluronidase for subcutaneous use shows similar efficacy and safety to IV form with less infusion reactions.
- It allows a larger injection volume, shorter administration time, and can be given on first dose unlike sub-Q rituximab.
MET Exon 14 Mutation Mechanism
- MET exon 14 skipping mutation removes an off switch in the MET receptor, causing unchecked activation.
- This activating mutation drives certain cancers by eliminating normal MET regulation.
Capmatinib Approved for MET Mutation
- MET exon 14 skipping mutations occur in about 3-5% of lung cancers and other malignancies.
- Capmatinib is FDA-approved for metastatic NSCLC patients with this mutation, including treatment-naive cases.